Blair William & Co. IL Grows Position in Cardiff Oncology, Inc. $CRDF

Blair William & Co. IL grew its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 44.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,524,118 shares of the company's stock after purchasing an additional 772,844 shares during the period. Blair William & Co. IL owned about 3.79% of Cardiff Oncology worth $7,951,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. SteelPeak Wealth LLC raised its stake in shares of Cardiff Oncology by 23.2% during the 2nd quarter. SteelPeak Wealth LLC now owns 22,800 shares of the company's stock worth $72,000 after buying an additional 4,300 shares during the period. Corebridge Financial Inc. raised its stake in shares of Cardiff Oncology by 40.8% during the 1st quarter. Corebridge Financial Inc. now owns 28,555 shares of the company's stock worth $90,000 after buying an additional 8,277 shares during the period. MetLife Investment Management LLC raised its stake in shares of Cardiff Oncology by 34.5% during the 1st quarter. MetLife Investment Management LLC now owns 35,726 shares of the company's stock worth $112,000 after buying an additional 9,167 shares during the period. Rhumbline Advisers raised its stake in shares of Cardiff Oncology by 18.8% during the 1st quarter. Rhumbline Advisers now owns 63,142 shares of the company's stock worth $198,000 after buying an additional 9,970 shares during the period. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Cardiff Oncology during the 2nd quarter worth approximately $32,000. Hedge funds and other institutional investors own 16.29% of the company's stock.

Cardiff Oncology Price Performance

Shares of Cardiff Oncology stock opened at $2.21 on Friday. The business has a 50-day moving average of $2.20 and a 200 day moving average of $2.87. Cardiff Oncology, Inc. has a 12 month low of $1.90 and a 12 month high of $5.64. The stock has a market capitalization of $147.03 million, a price-to-earnings ratio of -2.54 and a beta of 1.62.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.11 million. Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 77.94%. Equities research analysts anticipate that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Gary W. Pace purchased 275,000 shares of the business's stock in a transaction on Wednesday, July 30th. The shares were bought at an average price of $2.45 per share, with a total value of $673,750.00. Following the completion of the transaction, the director directly owned 1,330,676 shares in the company, valued at approximately $3,260,156.20. This represents a 26.05% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cardiff Oncology in a research note on Wednesday. Jefferies Financial Group started coverage on Cardiff Oncology in a research note on Tuesday, June 24th. They issued a "hold" rating and a $3.50 price objective for the company. William Blair reissued an "outperform" rating on shares of Cardiff Oncology in a research note on Wednesday, June 18th. HC Wainwright reduced their price objective on Cardiff Oncology from $18.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Finally, LADENBURG THALM/SH SH started coverage on Cardiff Oncology in a research note on Tuesday, July 8th. They issued a "buy" rating and a $19.00 price objective for the company. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $10.63.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Want to see what other hedge funds are holding CRDF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.